BHC’s $413M Move Could Transform Alcoholic Hepatitis Care!

Company Overview & Strategic Move into Liver Disease

Bausch Health Companies Inc. (NYSE/TSX: BHC), formerly known as Valeant Pharmaceuticals, is a diversified healthcare company with products spanning eye care, gastroenterology, and dermatology. Its portfolio includes the Bausch + Lomb vision business (contact lenses, surgical devices) and pharmaceuticals such as the GI drug Xifaxan (rifaximin). In July 2025, BHC made a bold strategic move by agreeing to acquire DURECT Corporation for an upfront $63 million (cash) plus contingent payouts up to $350 million tied to future sales (^[1]). This $413 million deal (total potential value) gives BHC rights to larsucosterol, DURECT’s phase 3–ready therapy for alcohol-associated hepatitis (AH) (^[1]) (^[1]). Larsucosterol is an epigenetic modulator with FDA Breakthrough Therapy Designation and could become the first approved treatment for severe alcoholic hepatitis, an area of high unmet need (^[1]).

BHC’s management highlights the acquisition as strengthening its liver disease pipeline – an important step as the company prepares for future challenges. Notably, Bausch expects to lose exclusivity on Xifaxan by 2028, which could erode a key revenue stream (^[2]). Larsucosterol’s phase 3 program is expected to yield data by 2027, and if successful, BHC could file for FDA approval, positioning this drug to launch around the time Xifaxan faces generic competition (^[2]) (^[2]). In essence, larsucosterol (a potential “blockbuster” per DURECT’s estimates) forms a pillar of Bausch’s strategy to rejuvenate its portfolio and potentially transform care for alcoholic hepatitis (^[2]) (^[2]). The optimism is tempered by larsucosterol’s past trial results – a Phase 2b study in 2023 missed its primary endpoint (90-day survival/transplant) (^[2]). However, promising secondary outcomes kept the program alive, and BHC’s deep resources will now fund the pivotal Phase 3 trial (^[2]) (^[2]). This calculated risk underpins BHC’s pivot toward innovative therapies, even as it continues to monetize its established product lines.

Dividend Policy & Cash Flow Profile

Dividend History: Bausch Health does not pay a dividend, and hasn’t distributed cash to shareholders in recent years. In fact, no dividends were declared or paid in 2020, 2021, or 2022, and the board has no plans to initiate dividends in the foreseeable future (^[3]). This stance is largely driven by BHC’s substantial debt load and covenants – its credit agreements restrict dividend payments while leverage remains high (^[3]). Management periodically reviews the policy, but priority has been given to debt reduction over shareholder yield (^[3]). As a result, BHC’s dividend yield is 0%, and income-focused investors have looked elsewhere (^[4]). The company’s limited free cash is being reinvested or reserved for liabilities rather than paid out.

Cash Flows: Although terms like AFFO/FFO are not applicable to a pharma company, Bausch does report adjusted cash flow metrics. For 2025, BHC (excluding Bausch + Lomb) is guiding for $0.825–$0.875 billion in Adjusted Cash Flow from Operations (^[5]). This suggests the core pharma segment should generate healthy operating cash to service debt and fund initiatives like the DURECT deal. Indeed, BHC has been directing cash towards deleveraging – for example, it announced plans to repay ~$900 million of debt with cash on hand after Q2 2025 (^[5]). Capital allocation remains defensive: management is prioritizing internal investments and debt paydown over shareholder returns. While this conserves cash, it also means equity holders see no direct cash yield for now. Any future dividend reinstatement likely hinges on achieving much lower leverage or a major asset sale to substantially reduce debt. Until then, creditors – not equity investors – effectively claim most of BHC’s free cash flow via interest and principal payments.

Leverage and Debt Maturities

Debt Load: High leverage is a defining feature – a legacy of the Valeant era’s acquisitive strategy. As of Q2 2025, Bausch Health carried about $21.7 billion in total long-term debt (gross) (^[5]). This is almost 8× its current market capitalization, underscoring why debt dominates any discussion of BHC’s finances. The debt is diversified across loans and bonds, but overall interest costs are significant. In the first half of 2025 alone, BHC’s interest expense was about $795 million, up from $705 million in H1 2024 (^[5]). Annualizing that run-rate puts interest near ~$1.6 billion for 2025 – an enormous drag on earnings. By comparison, BHC’s adjusted EBITDA for 2025 is forecast around $3.5 billion, implying interest coverage of barely ~2× (EBITDA/Interest) (^[5]) (^[5]). In other words, roughly half of BHC’s operating profit is absorbed by interest on its debt – a clear signal of financial strain. While the company is not in imminent default, this thin coverage highlights sensitivity to any cash flow shortfall or rising borrowing costs. It also explains why Bausch has been aggressively refinancing and extending debt maturities to buy time for turnaround efforts.

Maturity Profile: In 2025, management executed a major refinancing to push out looming maturities and avoid a near-term crunch (^[5]). The results are evident in the debt schedule: as of June 30, 2025, only $29 million of principal was due in the remainder of 2025 (versus ~$2.38 billion that had been due within 2025 as of Dec 2024) (^[5]). Bausch has essentially eliminated any large 2025–2027 maturities – just $660 million comes due in 2026 and $701 million in 2027, which should be manageable (^[5]). The heavy obligations now start in 2028, when about $6.2 billion of debt will mature, followed by $1.7 billion in 2029 (^[5]). Beyond that, BHC faces ~$4.0 billion due in 2030 and a massive $7.9 billion in 2031–2032 (^[5]). This restructured timeline gives the company a few years of breathing room – no giant wall of debt until 2028 – but it also concentrates a formidable repayment burden at the end of the decade. Bausch essentially kicked the can down the road, hoping to improve its financial position before the 2028–2032 obligations hit. The strategy buys time for BHC to execute its plans: expanding EBITDA (through growth initiatives like larsucosterol and new products), potentially selling assets (e.g. the B+L business), and accumulating cash for deleveraging. It’s worth noting that much of BHC’s debt is secured and covenant-heavy, limiting strategic flexibility. For example, the 2022 credit agreement restricts certain payments and requires BHC to maintain sufficient solvency (^[3]). The specter of bankruptcy was raised by a rumor in mid-2024 – a report suggested BHC might explore insolvency – causing its stock to plunge before management vehemently denied it (^[6]). While Bausch insists it is not considering bankruptcy, the incident highlighted how precarious investor confidence was (the stock hit multi-year lows on the rumor) (^[6]) (^[6]). In summary, BHC’s $21+ billion debt remains a central risk: the company must keep servicing this load (at ~$400 million+ in interest per quarter) and ultimately find ways to slash principal before the big 2028–2032 repayments become due.

Valuation and Comparables

Bausch Health’s equity valuation reflects its burdens and complexity. As of September 2025, BHC’s market capitalization is only around $2.7 billion (^[4]), a fraction of its ~$10 billion in annual revenues. This implies a Price/Sales ratio < 0.3, indicating the market assigns low value to each dollar of BHC’s sales – likely due to slim profit margins under heavy debt. Traditional P/E is not very meaningful for BHC; trailing GAAP earnings are modest or volatile (the company lost $54 million in the first half of 2024, then earned $90 million in the first half of 2025) (^[5]). On a forward basis, if BHC manages a few hundred million in net income, the P/E might appear in the low teens. However, analysts often prefer enterprise value metrics here. Enterprise Value (EV) – combining debt and equity – is roughly $24 billion (the $21.7B debt plus $2.7B equity). Against 2025 projected Adjusted EBITDA of ~$3.5B (^[5]), BHC’s EV/EBITDA is about 6.5–7×, which is actually in line with some pharma peers. For example, Teva (a larger generic drugmaker) trades around 7–8× earnings (^[4]). The difference is that Teva’s equity market cap is much larger (>$20B) because its debt is more moderate and its business less encumbered by uncertainty (^[4]). In contrast, Bausch’s equity is deeply discounted due to its leverage and looming patent cliff.

A sum-of-the-parts view highlights this discount. Bausch Health still owns approximately 88% of Bausch + Lomb (BLCO), the eye-care subsidiary it partially IPO’d in 2022 (^[7]). Bausch + Lomb’s current public market value is about $5.5 billion for 100% of the equity (^[8]). That implies BHC’s stake is worth roughly $4.8 billion on paper – nearly double BHC’s own market cap. In theory, if Bausch could monetize or spin off B+L at fair value, it might unlock significant value for shareholders. However, the market is skeptical BHC’s shareholders will ever fully realize that value. The “conglomerate discount” and debt overhang are so severe that BHC’s non-B+L businesses (gastroenterology, dermatology, etc.) are being valued at negative equity once the debt is accounted for. Essentially, investors suspect that creditors and structural challenges (taxes, covenants, etc.) would absorb most of the proceeds if B+L were sold. This skepticism is not unfounded: BHC’s attempt to spin off or distribute B+L stalled due to solvency concerns, and now the parent is exploring an outright sale of B+L to pay down debt (^[7]). Reports in late 2024 indicated private equity interest valuing B+L around $10–11.5 billion EV, but reaching a deal has been difficult (^[7]) (^[9]). Until there’s clearer progress on asset sales or a drastic debt paydown, BHC’s stock may continue to languish at a low multiple. It’s a case where the sum-of-parts value is high, but the path to unlocking it is uncertain – reflecting both opportunity and risk for investors willing to bet on a turnaround.

Key Risks and Red Flags

Investors in Bausch Health face several significant risks and potential red flags:

– High Leverage and Interest Burden: BHC’s ~6× leverage (Net Debt/EBITDA) is well above industry norms, leaving little room for error. Even after refinancing, the debt remains enormous at $21+ billion (^[5]). Rising interest rates or any dip in earnings could jeopardize coverage. With interest expense running ~$1.6B per year (^[5]), Bausch’s interest coverage is only ~2×, and cash flows are largely spoken for by creditors. This capital structure risk was underscored by last year’s bankruptcy rumor scare – a reminder that, despite management’s assurances, insolvency would become a real consideration if performance deteriorates or refinancing options dry up. The debt also constrains strategic moves (e.g. restricting dividends, as noted) and may necessitate asset sales under less-than-ideal conditions.

– Looming Patent Expiration (Xifaxan): A major concentration risk is BHC’s reliance on Xifaxan, a GI antibiotic for IBS-D and hepatic encephalopathy. Xifaxan has been Bausch’s top-selling pharmaceutical (a “blockbuster” with over $1 billion in annual sales) and a primary growth driver (^[5]). However, the company expects to face generic competition by 2028 after patent expiry (^[2]). Bausch successfully defended certain Xifaxan patents in court – blocking one generic challenger until October 2029 (^[10]) – but it has already agreed to let other generics (Teva, Sun, Sandoz) enter by mid-2028 as part of patent settlements (^[10]). In addition, Xifaxan was selected for Medicare price negotiation in 2027 (via the Inflation Reduction Act) (^[5]), which could cut its U.S. revenue even before generics arrive. The twin impact of price erosion and eventual generic entry means Bausch could see a steep drop in cash flows from 2027 onward. This is a central risk: without a comparable new revenue source by then, servicing the huge debt will become far more challenging. Management is trying to mitigate this – developing a new rifaximin formulation for a different indication (which is in Phase 3) (^[2]), and betting on pipeline assets like larsucosterol – but there’s no guarantee these will fully replace Xifaxan’s earnings.

– Regulatory and Pipeline Uncertainty: The DURECT acquisition and larsucosterol program illustrate pipeline risk. While there is a possibility of transforming alcoholic hepatitis care, the drug must still prove itself in Phase 3. Recall that larsucosterol’s Phase 2b trial failed to beat placebo on its primary endpoint (^[2]) – a red flag regarding efficacy. Bausch is effectively banking that further analysis and a new trial design will demonstrate a mortality benefit or clinical improvement sufficient for approval. If Phase 3 again falls short, the hoped-for blockbuster will not materialize (and BHC will have spent significant R&D and the $63M upfront for naught). Even if it succeeds technically, commercial uptake is an open question: for a new therapy in alcoholic hepatitis, educating physicians and payers will be critical, and competitors are also racing in earlier-stage trials (^[2]). More broadly, Bausch’s pharma pipeline is relatively thin after years of underinvestment (Valeant was known for cutting R&D). Aside from larsucosterol and the new rifaximin variant, there are few late-stage assets. This raises the stakes for each program – if these fail to deliver, BHC might face a growth gap when its older drugs mature.

– Asset Sale/Separation Risks: BHC’s plan to unlock value via separating Bausch + Lomb has been slow and fraught with hurdles. The 2022 IPO of B+L was only partial, and a subsequent full spin-off was blocked by creditor concerns (a required solvency test could not be met given BHC’s debt) (^[7]). Now the company is pursuing a sale of B+L to pay down debt, but potential buyers have reportedly balked at the price, given the high expectations (over $10B EV) (^[7]). If Bausch cannot successfully monetize B+L in a timely manner, it loses a key avenue for debt reduction. Conversely, if it does sell B+L, that removes a stable, cash-generative business (eye health) from the portfolio, leaving BHC even more concentrated in higher-risk pharma assets. In either scenario, execution is tricky: a fire-sale would destroy shareholder value, whereas holding on to B+L leaves the debt overhang in place. This uncertainty around strategic direction is a risk in itself – management is essentially trying to fix the balance sheet and invest for growth simultaneously, a delicate balancing act.

– Legacy Issues and Governance: Bausch (as Valeant) carries historical baggage – past accounting scandals, aggressive pricing practices, and legal entanglements. Although the company has since rebranded and improved compliance, some overhang remains. Shareholder lawsuits from the Valeant era were largely settled, but any resurgence of controversy could hurt the stock’s perception. Furthermore, BHC’s heavy use of non-GAAP adjustments (e.g. adding back amortization of intangibles, excluding many “one-time” expenses each quarter) can be viewed as a red flag. It makes it harder to assess the true sustainable earnings power. For instance, in Q2 2025 Bausch reported $148M GAAP net income but “Adjusted net income” of $335M after numerous exclusions (^[5]). The large gap is mainly due to intangible amortization and debt refinancing gains/losses, which are real economic costs for a company built via acquisitions. Investors should be cautious of overly rosy adjusted figures. Additionally, management turnover in recent years and the complexity of splitting off B+L have added governance challenges. Overall, while Bausch Health has worked to distance itself from past missteps, trust needs to be rebuilt, and any sign of slipping back (in transparency or business ethics) would be a serious red flag.

Open Questions and Outlook

The coming years will be pivotal for BHC. Several open questions remain unanswered, which will determine whether the company’s narrative turns from distressed to a successful turnaround:

– Can Bausch Deliver on Larsucosterol’s Promise? The headline of this report – a $413M move to transform alcoholic hepatitis care – hinges on larsucosterol’s fate. Will the Phase 3 trial confirm a meaningful benefit for patients with alcoholic hepatitis? Bausch is optimistic, but the earlier trial’s failure on the primary endpoint raises doubts (^[2]). If BHC can demonstrate improved survival or recovery in AH patients, larsucosterol could become a breakthrough therapy and a new revenue pillar by 2028. If not, Bausch will have to write off the investment and return to square one for its post-Xifaxan strategy. The outcome of this trial (expected top-line data by 2027 (^[2])) is one of the biggest binary events in BHC’s pipeline. Success could not only justify the $350M in milestone payments but also significantly bolster BHC’s growth profile; failure would leave a gap in the future portfolio and could spook investors and creditors alike.

– Will Bausch + Lomb Be Sold – And At What Price? The uncertainty around B+L’s ownership is a major strategic question. Bausch Health’s management has signaled willingness to fully separate or sell its 88% stake in B+L to reduce debt (^[7]). However, negotiations with prospective buyers (mainly private equity consortia) have been protracted, with reports that bidders are wary of overpaying (^[11]) (^[9]). If a sale materializes, the net proceeds will be crucial. BHC ideally wants a valuation north of $10 billion for B+L (^[7]); but if the market only offers, say, $8 billion, will Bausch accept? And after taxes or transaction costs, how much debt could truly be paid off? There’s also the question of timing – the longer this drags on, the more it distracts management and leaves the status quo of high leverage. Conversely, if no sale occurs, is there a Plan B? Bausch might revisit the idea of an equity spin-off or exchange offer (the earlier plan that got shelved) but would need creditor blessing and a much stronger balance sheet to pass solvency tests (^[7]). How this “crown jewel” asset gets resolved will heavily influence BHC’s future risk profile and shareholder value. Until then, investors are left guessing whether they effectively own a pharma business or a combined pharma/eye-care entity, and what the capital structure will look like in each scenario.

– Can BHC Reduce Debt Fast Enough? Bausch has taken steps to refinance and extend maturities, but ultimately the debt must be paid down to truly fix the balance sheet. Aside from selling B+L, the company’s other options include selling smaller non-core assets, using internal cash flows, or perhaps even issuing equity if the stock price improves. An open question is whether operational cash flow (plus any divestiture proceeds) will be sufficient to meaningfully lower leverage before the 2028 debt wave hits. BHC’s guidance of ~$0.8B adjusted cash from operations (ex-B+L) in 2025 (^[5]) suggests it can generate some surplus cash, but interest eats up a lot of that. Will there be room to, for example, retire a couple billion in debt over the next 2–3 years organically? Thus far, most deleveraging has come from asset moves (e.g. the 2022 IPO cash from B+L went toward debt). The pace of deleveraging is an open question: if it’s too slow, rating agencies and markets may remain unconvinced about BHC’s long-term solvency. Any additional bolt-on acquisitions (like DURECT) also need to be balanced against debt reduction. Investors will be watching how management prioritizes uses of cash – will they double down on paying debt with every spare dollar, and can they strike the right deals to lighten the load?

– What is the Long-Term Business Mix? Bausch Health today is a hybrid of a vision-care company and a specialty pharma company. Five years from now, what will it look like? Open questions include whether Bausch + Lomb will still be under the BHC umbrella or entirely separate. If larsucosterol succeeds, will Bausch pivot more toward innovative biotech-style development, or stick to its historical strategy of maximizing existing product franchises (like dermatology brands and generics)? There is also the Solta Medical aesthetics unit (maker of devices like Thermage) – might that be spun off or sold to raise cash, given it’s somewhat unrelated to core pharma? Clarity on the business focus is needed. A concern is that if B+L is sold, Bausch becomes a smaller, pure-pharma company but still with a big debt – essentially a highly leveraged specialty pharma with a narrower asset base. On the other hand, if B+L stays, can Bausch effectively manage two disparate segments and execute an R&D-intensive liver program simultaneously? The conglomerate structure vs. pure-play question remains unresolved. How BHC answers it (by either successfully separating businesses or by convincing the market of synergies in keeping them together) will influence its valuation and strategy going forward.

– Will Shareholders Ever See Returns? Finally, from an equity investor’s perspective, a lingering question is when – if ever – BHC will resume rewarding shareholders (either via dividends or share buybacks). Right now, all capital is going toward debt and reinvestment, which is understandable given the circumstances. But in the long run, companies need to demonstrate that equity holders can benefit from the business’s cash generation. If Bausch can navigate the next few years – avoiding default, launching new drugs, and cutting debt – one would expect a healthier financial position by, say, 2030. At that point, could a dividend be reinstated or meaningful buybacks occur? Or will the company still be shackled by obligations and growth projects? This hinges on the outcomes of all the above questions. For now, BHC is very much a “show me” story – investors will likely wait for concrete signs of reduced leverage and successful new product execution before pricing in any shareholder payouts. The unknown is whether that inflection point will come before current shareholders lose patience (or before any further distress).

In summary, Bausch Health’s $413 million bet on alcoholic hepatitis is an ambitious attempt to write the next chapter of its turnaround. If it pays off – alongside key moves like a value-unlocking sale of B+L – BHC could emerge in a few years as a leaner company with a fresh growth engine. However, the path is fraught with risks from all sides: scientific, financial, and operational. Execution will be critical. The coming 2–3 years should answer these open questions and determine whether Bausch Health can truly transform itself, just as it hopes to transform the care of liver disease patients in need. The stakes are high, but so is the potential reward if management’s strategies succeed against the odds.

Sources

1. https://sec.gov/Archives/edgar/data/885590/000119312525167139/d943437dsctoc.htm
2. https://fiercebiotech.com/biotech/bausch-health-bags-phase-3-ready-liver-prospect-63m-durect-buyout
3. https://fintel.io/doc/sec-bausch-health-companies-inc-885590-10k-2023-february-23-19412-3932
4. https://macrotrends.net/stocks/charts/BHC/bausch-health-cos/dividend-yield-history
5. https://biospace.com/press-releases/bausch-health-announces-second-quarter-2025-results
6. https://investopedia.com/bausch-health-says-it-isn-t-considering-bankruptcy-after-rumor-tanks-stock-8683136
7. https://ft.com/content/5272ebe0-146c-484c-8ae3-6fb6edc71fbb
8. https://finance.yahoo.com/quote/BLCO/
9. https://ft.com/content/52aaf972-1f3a-4017-b181-74c3a3c1e6ef
10. https://reuters.com/business/healthcare-pharmaceuticals/bausch-wins-us-appeal-block-alvogen-generic-diarrhea-drug-2024-04-11/
11. https://ft.com/content/ac60897d-b6cd-4cf2-b6de-5a3cc1bd2f51

For informational purposes only; not investment advice.